WO2003013553A1 - Fórmula de solución dialítica y procedimiento de diálisis gastrointestinal - Google Patents
Fórmula de solución dialítica y procedimiento de diálisis gastrointestinal Download PDFInfo
- Publication number
- WO2003013553A1 WO2003013553A1 PCT/MX2001/000061 MX0100061W WO03013553A1 WO 2003013553 A1 WO2003013553 A1 WO 2003013553A1 MX 0100061 W MX0100061 W MX 0100061W WO 03013553 A1 WO03013553 A1 WO 03013553A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- meq
- dialysis
- solution
- gastrointestinal
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
Definitions
- the invention participates in the field of medicine that relates to dialysis methods for treating kidney failure problems, as well as in the field of formulas for the preparation of medicaments or dialytic solutions useful for the gastrointestinal dialysis process.
- peritoneal dialysis consists in the use of a virtual cavity in the patient's peritoneum, which by means of a surgical intervention is conditioned with a catheter for the introduction and extraction of a dialytic solution, with which the elimination of toxic " elements is achieved.
- the peritoneum is used as a semipermeable membrane, to circulate the solutes of substances harmful to the human body, from the bloodstream to the other side of the permeable membrane, leaving the waste elements, on the side where the dialytic solution is found
- the way in which the unwanted solutes for the body are made to travel from the patient's bloodstream, to the dialytic solution, crossing the peritoneum, is by simple diffusion, What is it the chemical principle that describes the way in which solutes that are contained in two different solutions, separated by a semipermeable membrane, tend to balance; That is precisely what is achieved by interposing the peritoneum as a semipermeable membrane, between the bloodstream and the dialysis solution, so a low concentration of the solutes that is to be removed from the blood is left in the dialytic solution, and when both fluids are leveled , the concentration in the patient's blood is lowered, and the dialytic solution that concentrated the unwanted
- the patient's blood is circulated from his bloodstream, to an extracorporeal filter that has a synthetic semipermeable membrane through which toxic compounds are removed from the patient's blood, through osmosis processes and diffusion, and then pump the dialyzed blood back into the patient's bloodstream.
- peritoneal dialysis There is a therapeutic procedure for dialysis similar to that of peritoneal dialysis, in which the peritoneal membrane is replaced by a section of the large intestine, which is separated from the intestinal duct, and subsequently a pair of catheters, an entry one, is implanted. and an outlet, as well as a pump that circulates the dialytic solution from one end of the intestine to the other.
- This therapeutic procedure requires a surgical intervention to separate a section of intestine and condition it to be used exclusively in the dialysis process.
- This invention basically consists of a therapeutic method for performing gastrointestinal dialysis treatments, and in the formula of a dialytic solution especially for gastrointestinal dialysis, for oral administration.
- the method consists in circulating through the gastrointestinal tract of the patient an amount of the dialytic solution, which is generally seven liters per treatment in adults, in a period of generally four hours, time in the which is eliminated by an osmotic diarrhea induced precisely by the dialytic solution.
- the most important characteristics of the dialysis solution is that it causes an osmotic diarrhea in the patient and that it is administered orally.
- the most important characteristics of the therapeutic procedure of gastrointestinal dialysis is that in order to perform it, no surgery is required, nor the use or assistance of extracorporeal objects or devices for the administration thereof, it is only oral shots of dialysis solution.
- the pointer (1) shows the lumen of the intestine, which remains in contact with dialysis solution during the gastrointestinal dialysis process.
- the pointer (2) shows the intestinal membrane, which is in turn composed of the different layers or sections shown in Figure 2.
- the pointer (3) shows the capillary light, which carries the bloodstream.
- the pointer (4) shows the basement membrane, which is precisely the permeable component of the capillary vessel.
- the pointer (5) shows the villi of the inner wall of the intestine.
- the pointer (6) shows the mucosa of the intestinal wall.
- the pointer (7) shows the submucosa of the intestinal wall.
- the pointer (8) shows the circular muscle of the intestine.
- the pointer (9) shows the longitudinal muscle of the intestine.
- Figure 1 shows a cross section of a section of the intestine, where the cross section of a capillary vessel can also be seen.
- This figure does not keep real proportions of the size relationship between the intestinal duct and the blood duct, because in reality, the intestinal duct is hundreds of times larger than the capillaries.
- broad strokes which are the elements that make up the semipermeable membrane that have to pass through the solutes that are extracted from the blood in the gastrointestinal dialysis process, to take them, by diffusion, to the dialytic solution that is found precisely in the gastrointestinal tract (1).
- the semipermeable membrane for the process of The diffusion is composed of the intestinal membrane (2) and the basal membrane of the capillary (4), so when the dialytic solution enters the gastrointestinal tract (1), due to the diffusion principle, its solutes tend to balance its concentration, with the concentration with which they are found in the blood that circulates in the blood duct (3) that is on the other side of the semipermeable membrane (which are precisely the intestinal and basal membranes); and since the concentration of the solutes is less or non-existent in the dialytic solution with respect to the blood, the movement of solutes occurs precisely from the blood, towards the dialytic solution, and thus the toxic solutes are extracted from the patient's blood.
- Figure 2 shows a cross section of the intestine, enlarged but with real proportions, where the different layers that integrate it are shown.
- villi which form a wide contact surface between the dialytic solution and the tissues that serve as a semipermeable membrane for osmosis and diffusion processes.
- capillary vessels There are thousands of capillary vessels that are present in each and every one of the layers or sections that are presented in the drawing, but their size is so small, that they are not visible in the dimensional proportion that was used for the drawing, so which are represented in the form of points. It is important to mention that most of the exchange of solutes that is performed with gastrointestinal dialysis, happens through the walls of the intestine, but the process begins in the mouth and ends in the rectum of the patient.
- the formula of the dialytic solution that is intended to be claimed by virtue of the present patent, and which is absolutely necessary for the practice of gastrointestinal dialysis, is as follows: Sodium from 30 mEq / l to 155 mEq / l
- Osmolalidac i from 500mOsm / k to 900 mOsm / k
- Sorbitol or similar compounds such as Xylitol, Lactitol, Maltitol, Arabinol, Inositol and Isomaltitol (or combinations of any of these), whose molecular structure is sufficiently large, may also be used. to prevent its passage through the gastrointestinal membrane and the basement membrane.
- the osmolality given to the dialytic solution is absolutely novel in the field of dialytic solutions, and it is precisely such osmolality that has the effect of producing an osmotic diarrhea. , which turns out to be indispensable for gastrointestinal dialysis.
- a base of bi-distilled water is generally used, at room temperature.
- This invention relates to the dialysis method which consists in introducing a dialytic solution (the formula of which is the subject of claims in the present patent document), by means of oral intake, in the stomach, in the small intestine and in the large intestine of the patient, which will initiate a process of diffusion of solutes between those contained in the patient's blood, and the contents or nonexistent in the dialysis solution.
- the diffusion of solutes will result in the balance between the amount of solutes contained in the blood and in the dialysis solution, thus tending to normalize the concentrations of such solute compounds in the patient's blood.
- the dialytic solution contains concentrations of such compounds, in amounts sufficient to achieve the balance of their presence in the blood.
- the way in which the chemical diffusion process is used, for the gastrointestinal dialysis method is similar to the way in which it is used for peritoneal dialysis, but the great particularity presented in the invention described is that in This method, the semipermeable membrane for the conduction of solutes, is mainly composed of the mucosa and submucosa of the digestive tract, as well as the basement membrane of the blood ducts that surround the stomach and intestine, so that the solutes that are You want to eliminate, transit from the blood duct to the gastrointestinal duct.
- the formula of the dialytic solution contains an element (Mannitol is generally used), which due to the high size of its molecules does not cross the semipermeable membrane, and induces an osmotic reaction that accelerates the conduction of solutes to be eliminated. , from the bloodstream to the dialysis solution.
- the entire process of exchanging solutes, using the walls of the gastrointestinal ducts as a permeable membrane, is benefited by how wide the surface of contact with the dialytic solution is, since precisely the gastrointestinal tract turns out to be sufficiently wide, to allow solute movement as large as necessary to remove unwanted toxic compounds from the patient's body.
- the ingestion of the same results in the induction in the patient of an osmotic diarrhea, which allows the circulation of the solution that has been exposed to diffusion, preventing it from being reabsorbed by the intestine, and also preventing fluid congestion in the patient's gastrointestinal system, thus allowing constant and relatively rapid administration of the dialytic solution in the patient, to achieve dialysis.
- the patient does not require any practical or professional help, since it is an oral administration solution, which does not happen in the case of hemodialysis that requires expert management of the device to which the patient is connected, especially since these devices are usually found in hospitals or dialysis centers, since very few patients are in technical and economic conditions to acquire and maintain such an apparatus.
- peritoneal dialysis due to the patient's lack of mobility, which is connected by a hose that comes out of his abdomen, to the dialysis solution containers, he loses mobility, and it is quite common that he requires help from other people.
- the described gastrointestinal dialysis method is applied by circulating through the gastrointestinal tract of the patient, an amount of the dialytic solution mentioned in this description, which is generally one liter per 10 kilos of the patient's weight, up to a maximum of seven liters per treatment, in a period of generally four hours, during which time it is eliminated by an osmotic diarrhea induced precisely by the dialytic solution.
- the dialytic solution is administered orally, usually at room temperature.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- External Artificial Organs (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/MX2001/000061 WO2003013553A1 (es) | 2001-08-10 | 2001-08-10 | Fórmula de solución dialítica y procedimiento de diálisis gastrointestinal |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/MX2001/000061 WO2003013553A1 (es) | 2001-08-10 | 2001-08-10 | Fórmula de solución dialítica y procedimiento de diálisis gastrointestinal |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003013553A1 true WO2003013553A1 (es) | 2003-02-20 |
Family
ID=19741786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MX2001/000061 WO2003013553A1 (es) | 2001-08-10 | 2001-08-10 | Fórmula de solución dialítica y procedimiento de diálisis gastrointestinal |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2003013553A1 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7053059B2 (en) | 2003-07-25 | 2006-05-30 | Baxter International Inc. | Dialysis solutions with reduced levels of glucose degradation products |
US7208479B2 (en) | 1998-12-04 | 2007-04-24 | Baxter International, Inc. | Peritoneal dialysis solution containing modified icodextrins |
-
2001
- 2001-08-10 WO PCT/MX2001/000061 patent/WO2003013553A1/es active Application Filing
Non-Patent Citations (2)
Title |
---|
MISKOWIAK, J.: "Continuous Intestinal Dialysis for Uraemia by Intermitent Oral intake of Non-absorbable Solutions.", SCAND. J. UROL. NEPHROL., vol. 25 (1), 7 March 1990 (1990-03-07), pages 71 - 74, XP002191919 * |
TANG, C.K. ET AL: "Home treatment of Uremia with Gastrointestinal Dialysis.", CLINICAL NEPHROLOGY, vol. 10, no. 1, 1978, pages 21 - 26, XP002191920 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7208479B2 (en) | 1998-12-04 | 2007-04-24 | Baxter International, Inc. | Peritoneal dialysis solution containing modified icodextrins |
US7053059B2 (en) | 2003-07-25 | 2006-05-30 | Baxter International Inc. | Dialysis solutions with reduced levels of glucose degradation products |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Campbell-Falck et al. | The intravenous use of coconut water | |
Pond et al. | Randomized study of the treatment of phenobarbital overdose with repeated doses of activated charcoal | |
ES2841099T3 (es) | Soluciones a base de bicarbonato para terapias de diálisis | |
Lansford et al. | The treatment of retained stones in the common bile duct with sodium cholate infusion | |
ES2395431T3 (es) | Agente para estimular en drenaje linfático | |
Carloss et al. | Acute renal failure from precipitation of cryoglobulins in a cool operating room | |
WO2003013553A1 (es) | Fórmula de solución dialítica y procedimiento de diálisis gastrointestinal | |
Juggi | Extracorporeal cation‐exchange circuits in the treatment of hyperammonaemia of hepatic failure | |
Mandelbaum et al. | Severe methyprylon intoxication treated by hemodialysis | |
Boddie | Transient ischaemic attacks and stroke due to extracranial aneurysm of internal carotid artery. | |
Tait | ON THE CURE OF THE CHRONIC PERFORATING ULCER OF THE BLADDER BY THE FORMATION OF AN ARTIFICIAL VESICO-VAGINAL FISTULA: AS PRACTISED BY THE LATE SIR JY SIMPSON | |
Ogilvie | The Surgery of Gall Stones: Lecture delivered at the Royal College of Surgeons of England on 16th April 1957 | |
Ross et al. | Haemodialysis and peritoneal dialysis | |
Localio et al. | Peritoneal irrigation: Successful use in the treatment of a case of renal failure due to mercurial nephrosis | |
Levin | Death due to gangrenous cholecystitis and peritonitis following unrelated surgery | |
RU2360705C1 (ru) | Способ применения изолированной петли тонкой кишки в качестве искусственной биологической почки | |
Grzegorzewska | Perforation of the transverse colon caused by a permanent peritoneal dialysis catheter | |
Sharpstone et al. | Retinal detachment with spontaneous regression in renal failure. | |
Frenckner et al. | Patient complications during extracorporeal membrane oxygenation (ECMO) | |
Karelitz et al. | Treatment of alimentary toxicosis | |
Kinney | Renal Replacement Therapy | |
Haffner et al. | Dialysis | |
WARNER et al. | The Cast Syndrome: AN UNUSUALLY SEVERE CASE | |
Notelovitz, M., Dalrymple, D. & Funston | Acute renal failure following quinine poisoning | |
Al-Salem et al. | Gastrointestinal complications of sickle cell anemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EE ES FI GB GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ PL PT RO RU SD SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZW AM AZ BY KG KZ MD TJ TM AT BE CH CY DE DK ES FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |